Krystal BiotechKRYS
KRYS
About: Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Employees: 275
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
207% more call options, than puts
Call options by funds: $54.2M | Put options by funds: $17.6M
121% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 29
17% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 7 (+1) [Q1 2025]
13% more capital invested
Capital invested by funds: $4.35B [Q4 2024] → $4.93B (+$575M) [Q1 2025]
13% more funds holding
Funds holding: 263 [Q4 2024] → 296 (+33) [Q1 2025]
1.73% less ownership
Funds ownership: 96.57% [Q4 2024] → 94.84% (-1.73%) [Q1 2025]
22% less repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 111
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$155
1%
upside
Avg. target
$194
27%
upside
High target
$240
57%
upside
7 analyst ratings
5 positive
71%
2 neutral
29%
0 negative
0%
Chardan Capital Geulah Livshits | 43%upside $219 | Buy Maintained | 25 Jul 2025 |
HC Wainwright & Co. Joseph Pantginis | 57%upside $240 | Buy Reiterated | 25 Jul 2025 |
B of A Securities Alec Stranahan | 25%upside $192 | Buy Maintained | 22 Jul 2025 |
Citigroup Carly Kenselaar | 15%upside $176 | Neutral Maintained | 10 Jul 2025 |
Clear Street Bill Maughan | 24%upside $190 | Buy Initiated | 1 Jul 2025 |
Financial journalist opinion
Based on 5 articles about KRYS published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Krystal Biotech, Inc. (KRYS) to Report Q2 Results: Wall Street Expects Earnings Growth
Krystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
5 days ago
Krystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
VYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family
Neutral
GlobeNewsWire
6 days ago
Jeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the Décolleté
KB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally reverse the biology of aging skin, announced today positive safety and efficacy results, including significant improvements in key skin aesthetic attributes such as wrinkles and elasticity, in PEARL-2, a randomized, double-blind, placebo-controlled Phase 1 study evaluating KB304, for the treatment of wrinkles of the décolleté. Meaningful aesthetic improvements were reported following KB304 treatment with clear and statistically significant advantages over placebo as evaluated by both the investigator and subjects using the Global Aesthetic Improvement Scale (GAIS).
Neutral
Zacks Investment Research
2 weeks ago
KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up
Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.
Neutral
GlobeNewsWire
3 weeks ago
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
Eye drop administration of KB801 designed to enable sustained expression of NGF in the front of the eye Investor call and webcast to be held July 9 at 8:30 am ET to discuss program and trial design PITTSBURGH, July 09, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 1/2 clinical trial (“EMERALD-1”), a 2:1 randomized, double-masked, multicenter, placebo-controlled study evaluating KB801 for the treatment of neurotrophic keratitis (NK). “Our ophthalmology pipeline is well under way with the dosing of our first patient in EMERALD-1, along with initiation of our Phase 3 IOLITE study in DEB,” said Suma Krishnan, President, Research & Development, Krystal Biotech, Inc. “Until now, rapid protein clearance rates and high cell turnover in the front of the eye have severely limited the therapeutic potential of biologics and gene therapies for the treatment of corneal epithelial defects and other front of the eye diseases.
Positive
The Motley Fool
1 month ago
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.
Positive
Zacks Investment Research
1 month ago
3 Promising Genomics Stocks to Keep an Eye On in 2025
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Negative
Zacks Investment Research
1 month ago
KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study
Krystal Biotech rises 4% after dosing begins in a phase III study of KB803 eye drops to treat rare DEB-related corneal damage.
Positive
Zacks Investment Research
1 month ago
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?
Krystal Biotech (KRYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
GlobeNewsWire
1 month ago
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
Intra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated and associated with full corneal healing by 3 months as well as significant visual acuity improvement from hand motion to 20/25 at 8 months PITTSBURGH, June 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the first patient has been dosed in its Phase 3 clinical trial (“IOLITE”), an intra-patient, double-blind, multicenter, placebo-controlled study with crossover design evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa (DEB) patients. KB803 is designed to deliver two copies of the COL7A1 transgene to the corneal epithelium and enable local type VII collagen production in the front of the eye.
Charts implemented using Lightweight Charts™